nach oben

High Blood Pressure & Cardiovascular Prevention

Erschienen in:

25.02.2023 | Original article

Association of CYP2C19 Polymorphic Markers with Cardiovascular Disease Risk Factors in Gas Industry Workers Undergoing Periodic Medical Examinations

verfasst von: Dmitry Alekseevich Sychev, MD, DSci, Professor, Academician of the Russian Academy of Sciences, rector, head of Clinical Pharmacology and Therapy department, Olga Alexandrovna Polyakova, MD, PhD, Assistant of the Department of Therapy and Polymorbid Pathology named after academician M.S. Vovsi, Zhannet Alimovna Sozaeva, MD, researcher in the Department of Molecular Medicine, Karin Badavievich Mirzaev, MD, DSci, vice-rector for research and innovation, director of the Research Institute of Molecular and Personalized Medicine, Olga Dmitrievna Ostroumova, MD, DSci, Professor, head of the Department of Therapy and Polymorbid Pathology named after Academician M.S. Vovsi

Erschienen in: High Blood Pressure & Cardiovascular Prevention | Ausgabe 2/2023

Einloggen, um Zugang zu erhalten

Abstract

Introduction

Human cytochrome P450 (CYP) enzymes have a wide range of endogenous substrates and play a crucial role in cardiovascular physiology as well as in metabolic processes, so the issue of cytochrome P450 genes investigation has received considerable critical attention in the prevention of cardiovascular diseases (CVDs).

Aim

Comprehensive assessment of relationship between CYP2C19*2, CYP2C19*3 polymorphisms and CVD risk factors in gas industry workers undergoing periodic medical examination (PME).

Materials and Methods

The study included 193 gas industry workers aged 30–55 years without acute diseases as well as exacerbations of chronic diseases, diabetes mellitus, and CVD history. CYP2C19 (rs4244285 and rs4986893) genotyping and analysis of the relationship between CYP2C19*2 and CYP2C19*3 and CVD risk factors were performed.

Results

The CYP2C19*2 (A) and CYP2C19*3 (A) loss-of-function alleles frequencies were 20% and 2%, respectively. The frequency of high-normal blood pressure (BP) (130–139 and/or 85–89 mm Hg) detection was higher in the CYP2C19*2 (A) subgroup compared with wild-type GG allele carriers (26.7% vs. 5.2%, p = 0.03) in individuals without arterial hypertension (AH) and BP ≥ 140 and/or 90 mm Hg on PME. The median systolic BP levels were 5 mm Hg higher in CYP2C19*2 (A) group than in CYP2C19*2 (GG) group (125 vs. 120 mm Hg, p = 0.01). There was a similar trend for diastolic BP (85 vs. 80 mmHg, p = 0.08). CYP2C19*2 (A) was associated with higher mean levels of both systolic and diastolic BP (p = 0.015 and p = 0.044, respectively) in patients with AH. CYP2C19*2 was not associated with the other CVD risk factors analyzed.

Conclusion

The association of CYP2C19*2 with BP level suggests a possible role of this factor in AH development, which requires further research.

Nur mit Berechtigung zugänglich

Roth GA, Mensah GA, Johnson CO, Addolorato G, Ammirati E, Baddour LM, Barengo NC, Beaton AZ, Benjamin EJ, Benziger CP, Bonny A, Brauer M, Brodmann M, Cahill TJ, Carapetis J, Catapano AL, Chugh SS, Cooper LT, Coresh J, Criqui M, DeCleene N, Eagle KA, Emmons-Bell S, Feigin VL, Fernández-Solà J, Fowkes G, Gakidou E, Grundy SM, He FJ, Howard G, Hu F, Inker L, Karthikeyan G, Kassebaum N, Koroshetz W, Lavie C, Lloyd-Jones D, Lu HS, Mirijello A, Temesgen AM, Mokdad A, Moran AE, Muntner P, Narula J, Neal B, Ntsekhe M, de Moraes G, Otto C, Owolabi M, Pratt M, Rajagopalan S, Reitsma M, Ribeiro ALP, Rigotti N, Rodgers A, Sable C, Shakil S, Sliwa-Hahnle K, Stark B, Sundström J, Timpel P, Tleyjeh IM, Valgimigli M, Vos T, Whelton PK, Yacoub M, Zuhlke L, Murray C, Fuster V. GBD-NHLBI-JACC Global Burden of Cardiovascular Diseases writing Group. Global Burden of Cardiovascular Diseases and Risk factors, 1990–2019: update from the GBD 2019 study. J Am Coll Cardiol. 2020;76(25):2982–3021. https://doi.org/10.1016/j.jacc.2020.11.010.CrossRefPubMedPubMedCentral

Rosstat. Russian Statistical Yearbook. 2021. Moscow: Stat. book; 2021. (In Russ.) https://rosstat.gov.ru/storage/mediabank/Ejegodnik_2021.pdf. Accessed 29.08.2022.

Cardiovascular prevention 2017. National guidelines. Russian J Cardiol. 2018;67–122. https://doi.org/10.15829/1560-4071-2018-6-7-122. (In Russ.).

Barbarash OL, Sedykh DYu, Bykova IS, Kashtalap VV, Erlich AD. Risk factors, clinical features of the course of myocardial infarction and treatment of young patients based on two hospital registries. Ration Pharmacotherapy Cardiol. 2020;16(2):250–7. https://doi.org/10.20996/1819-6446-2020-04-01. (In Russ.).CrossRef

Chistik T. Rejuvenation of myocardial infarctions and strokes: modern methods of prevention. Arterial Hypertens. 2016;4(48):57–62. Accessed 29.08.2022. https://cyberleninka.ru/article/n/omolozhenie-infarktov-miokarda-i-insultov-sovremennye-metody-profilaktiki.

Yang Y, Zhang Y, Ren M, Wang Y, Cairang Z, Lin R, Sun H, Liu J. Association of cytochrome P450 2C19 polymorphisms with coronary heart disease risk: a protocol for systematic review and meta-analysis. Med (Baltim). 2020;99(50):e23652. https://doi.org/10.1097/MD.0000000000023652.CrossRef

Elfaki I, Mir R, Almutairi FM, Duhier FMA. Cytochrome P450: polymorphisms and roles in Cancer, Diabetes and Atherosclerosis. Asian Pac J Cancer Prev. 2018;19(8):2057–70. https://doi.org/10.22034/APJCP.2018.19.8.2057.CrossRefPubMedPubMedCentral

Zordoky BN, El-Kadi AO. Effect of cytochrome P450 polymorphism on arachidonic acid metabolism and their impact on cardiovascular diseases. Pharmacol Ther. 2010;125(3):446–63. https://doi.org/10.1016/j.pharmthera.2009.12.002.CrossRefPubMed

Frye RF, Schneider VM, Frye CS, Feldman AM. Plasma levels of TNF-alpha and IL-6 are inversely related to cytochrome P450-dependent drug metabolism in patients with congestive heart failure. J Card Fail. 2002;8(5):315–9. https://doi.org/10.1054/jcaf.2002.127773.CrossRefPubMed

10.

Zhang YY, Zhou X, Ji WJ, Liu T, Ma J, Zhang Y, Li YM. Association between CYP2C19*2/*3 polymorphisms and Coronary Heart Disease. Curr Med Sci. 2019;39(1):44–51. https://doi.org/10.1007/s11596-019-1998-2.CrossRefPubMed

11.

Shin DJ, Kwon J, Park AR, Bae Y, Shin ES, Park S, Jang Y. Association of CYP2C19*2 and *3 genetic variants with essential hypertension in Koreans. Yonsei Med J. 2012;53(6):1113–9. https://doi.org/10.3349/ymj.2012.53.6.1113.CrossRefPubMedPubMedCentral

12.

Akasaka T, Sueta D, Arima Y, Tabata N, Takashio S, Izumiya Y, Yamamoto E, Yamamuro M, Tsujita K, Kojima S, Kaikita K, Kajiwara A, Morita K, Oniki K, Saruwatari J, Nakagawa K, Ogata Y, Matsui K, Hokimoto S. Association of CYP2C19 variants and epoxyeicosatrienoic acids on patients with microvascular angina. Am J Physiol Heart Circ Physiol. 2016;311(6):H1409–15. https://doi.org/10.1152/ajpheart.00473.2016.CrossRefPubMed

13.

Shahabi P, Siest G, Meyer UA, Visvikis-Siest S. Human cytochrome P450 epoxygenases: variability in expression and role in inflammation-related disorders. Pharmacol Ther. 2014;144(2):134–61. https://doi.org/10.1016/j.pharmthera.2014.05.011.CrossRefPubMed

14.

Pharmacogene Variation Consortium (PharmVar). CYP2C19 (Updated Aug 9 2022). https://www.pharmvar.org/gene/CYP2C19. Accessed 29.08.2022.

15.

Bertrand-Thiébault C, Berrahmoune H, Thompson A, Marie B, Droesch S, Siest G, Foernzler D, Visvikis-Siest S. Genetic polymorphism of CYP2C19 gene in the Stanislas cohort. A link with inflammation. Ann Hum Genet. 2008;72(Pt 2):178–83. https://doi.org/10.1111/j.1469-1809.2007.00417.x.CrossRefPubMed

16.

Akasaka T, Sueta D, Arima Y, Tabata N, Takashio S, Izumiya Y, Yamamoto E, Tsujita K, Kojima S, Kaikita K, Kajiwara A, Morita K, Oniki K, Saruwatari J, Nakagawa K, Hokimoto S. CYP2C19 variants and epoxyeicosatrienoic acids in patients with microvascular angina. Int J Cardiol Heart Vasc. 2017;15:15–20. https://doi.org/10.1016/j.ijcha.2017.03.001.CrossRefPubMedPubMedCentral

17.

Bai Y, Huang R, Wan L, Zhao R. Association between CYP2C19 gene polymorphisms and lipid metabolism in chinese patients with ischemic stroke. J Int Med Res. 2020;48(7):300060520934657. https://doi.org/10.1177/0300060520934657.CrossRefPubMed

18.

Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, Clement DL, Coca A, de Simone G, Dominiczak A, Kahan T, Mahfoud F, Redon J, Ruilope L, Zanchetti A, Kerins M, Kjeldsen SE, Kreutz R, Laurent S, Lip GYH, McManus R, Narkiewicz K, Ruschitzka F, Schmieder RE, Shlyakhto E, Tsioufis C, Aboyans V, Desormais I, ESC Scientific Document Group. ;. 2018 ESC/ESH Guidelines for the management of arterial hypertension [published correction appears in Eur Heart J. 2019 Feb 1;40(5):475]. Eur Heart J. 2018;39(33):3021–3104. https://doi.org/10.1093/eurheartj/ehy339

19.

Botton MR, Whirl-Carrillo M, Del Tredici AL, Sangkuhl K, Cavallari LH, Agúndez JAG, Duconge J, Lee MTM, Woodahl EL, Claudio-Campos K, Daly AK, Klein TE, Pratt VM, Scott SA, Gaedigk A. PharmVar GeneFocus: CYP2C19. Clin Pharmacol Ther. 2021;109(2):352–66. https://doi.org/10.1002/cpt.1973.CrossRefPubMed

20.

Mirzaev KB, Zelenskaya EM, Barbarash OL, Ganyukov VI, Apartsin KA, Saraeva NO, Nikolaev KY, Ryzhikova KA, Lifshits GI, Sychev DA. CYP2C19 polymorphism frequency in russian patients in Central Russia and Siberia with acute coronary syndrome. Pharmgenomics Pers Med. 2017;10:107–14. https://doi.org/10.2147/PGPM.S126305.CrossRefPubMedPubMedCentral

21.

Persson A, Sim SC, Virding S, Onishchenko N, Schulte G, Ingelman-Sundberg M. Decreased hippocampal volume and increased anxiety in a transgenic mouse model expressing the human CYP2C19 gene. Mol Psychiatry. 2014;19(6):733–41. https://doi.org/10.1038/mp.2013.89.CrossRefPubMed

22.

Rendic SP, Guengerich FP. Human Family 1–4 cytochrome P450 enzymes involved in the metabolic activation of xenobiotic and physiological chemicals: an update. Arch Toxicol. 2021;95(2):395–472. https://doi.org/10.1007/s00204-020-02971-4.CrossRefPubMedPubMedCentral

23.

Moyer AM, Matey ET, Miller VM. Individualized medicine: sex, hormones, genetics, and adverse drug reactions. Pharmacol Res Perspect. 2019;7(6):e00541. https://doi.org/10.1002/prp2.541.CrossRefPubMedPubMedCentral

24.

Mwinyi J, Cavaco I, Pedersen RS, Persson A, Burkhardt S, Mkrtchian S, Ingelman-Sundberg M. Regulation of CYP2C19 expression by estrogen receptor: implications for estrogen-dependent inhibition of drug metabolism. Mol Pharmacol. 2010;78(5):886–94. https://doi.org/10.1124/mol.110.065540.CrossRefPubMed

25.

Mauvais-Jarvis F, Clegg DJ, Hevener AL. The role of estrogens in control of energy balance and glucose homeostasis. Endocr Rev. 2013;34(3):309–38. https://doi.org/10.1210/er.2012-1055.CrossRefPubMedPubMedCentral

26.

Gaio V, Nunes B, Fernandes A, Mendonça F, Horta Correia F, Beleza A, Gil AP, Bourbon M, Vicente A, Dias CM, Barreto da Silva M. Genetic variation at the CYP2C19 gene associated with metabolic syndrome susceptibility in a South Portuguese population: results from the pilot study of the European Health Examination Survey in Portugal. Diabetol Metab Syndr. 2014;6(1):23. https://doi.org/10.1186/1758-5996-6-23.CrossRefPubMedPubMedCentral

27.

Cardoso JV, Abrão MS, Berardo PT, Ferrari R, Nasciutti LE, Machado DE, Perini JA. Role of cytochrome P450 2C19 polymorphisms and body mass index in endometriosis: a case-control study. Eur J Obstet Gynecol Reprod Biol. 2017;219:119–23. https://doi.org/10.1016/j.ejogrb.2017.10.027.CrossRefPubMed

28.

Wang B, Wu L, Chen J, Dong L, Chen C, Wen Z, Hu J, Fleming I, Wang DW. Metabolism pathways of arachidonic acids: mechanisms and potential therapeutic targets. Signal Transduct Target Ther. 2021;6(1):94. https://doi.org/10.1038/s41392-020-00443-w.CrossRefPubMedPubMedCentral

29.

Biffi A, Gallo G, Fernando F, Sirico F, Signorello MG, Messina M, Manole G, Triglione N, Volpe M. Usefulness of the corporate wellness projects in primary prevention at the population level: a study on the prevalence, awareness, and control of hypertension in the Ferrari company. J Hum Hypertens. 2022;36(3):308–14. https://doi.org/10.1038/s41371-021-00528-1.CrossRefPubMed

30.

Biffi A, Gallo G, Fernando F, Sirico F, Signorello MG, De Martino L, Manole GE, Palermi S, Volpe M. Relationship between Cardiorespiratory Fitness, Baseline Blood pressure and hypertensive response to Exercise in the Ferrari Corporate Population. High Blood Press Cardiovasc Prev. 2022;29(1):81–8. https://doi.org/10.1007/s40292-021-00491-5.CrossRefPubMed

31.

Khalighi K, Cheng G, Mirabbasi S, Khalighi B, Wu Y, Fan W. Association of CYP2C19*2 with hyperlipidemia in patients with the wild-type CYP2C9. Genet Mol Res. 2017;16(3):gmr16039737. https://doi.org/10.4238/gmr16039737.CrossRef

32.

Babushkina NP, Postrigan AE, Kucher AN, Shipulin VM. Associations of rs4244285 in the CYP2C19 gene with multifactorial diseases. Siberian J Clin Experimental Med. 2021;36(4):125–31. https://doi.org/10.29001/2073-8552-2021-36-4-125-131. (In Russ.).CrossRef

33.

Polonikov A, Bykanova M, Ponomarenko I, Sirotina S, Bocharova A, Vagaytseva K, Stepanov V, Churnosov M, Bushueva O, Solodilova M, Shvetsov Y, Ivanov V. The contribution of CYP2C gene subfamily involved in epoxygenase pathway of arachidonic acids metabolism to hypertension susceptibility in russian population. Clin Exp Hypertens. 2017;39(4):306–11. https://doi.org/10.1080/10641963.2016.1246562.CrossRefPubMed

34.

Tsai MJ, Chang WA, Tsai PH, Wu CY, Ho YW, Yen MC, Lin YS, Kuo PL, Hsu YL. Montelukast induces apoptosis-inducing factor-mediated cell death of Lung Cancer cells. Int J Mol Sci. 2017;18(7):1353. https://doi.org/10.3390/ijms18071353.CrossRefPubMedPubMedCentral

35.

Sarkis A, Roman RJ. Role of cytochrome P450 metabolites of arachidonic acid in hypertension. Curr Drug Metab. 2004;5(3):245–56. https://doi.org/10.2174/1389200043335603.CrossRefPubMed

36.

Randriamboavonjy V, Busse R, Fleming I. 20-HETE-induced contraction of small coronary arteries depends on the activation of rho-kinase. Hypertension. 2003;41(3 Pt 2):801–6. https://doi.org/10.1161/01.HYP.0000047240.33861.6B.CrossRefPubMed

37.

Zhou Y, Khan H, Xiao J, Cheang WS. Effects of Arachidonic Acid Metabolites on Cardiovascular Health and Disease. Int J Mol Sci. 2021;22(21):12029. https://doi.org/10.3390/ijms222112029.CrossRefPubMedPubMedCentral

38.

Miyata N, Roman RJ. Role of 20-hydroxyeicosatetraenoic acid (20-HETE) in vascular system. J Smooth Muscle Res. 2005;41(4):175–93. https://doi.org/10.1540/jsmr.41.175.CrossRefPubMed

39.

Singh H, Cheng J, Deng H, Kemp R, Ishizuka T, Nasjletti A, Schwartzman ML. Vascular cytochrome P450 4A expression and 20-hydroxyeicosatetraenoic acid synthesis contribute to endothelial dysfunction in androgen-induced hypertension. Hypertension. 2007;50(1):123–9. https://doi.org/10.1161/HYPERTENSIONAHA.107.089599.CrossRefPubMed

40.

Cheng J, Wu CC, Gotlinger KH, Zhang F, Falck JR, Narsimhaswamy D, Schwartzman ML. 20-hydroxy-5,8,11,14-eicosatetraenoic acid mediates endothelial dysfunction via IkappaB kinase-dependent endothelial nitric-oxide synthase uncoupling. J Pharmacol Exp Ther. 2010;332(1):57–65. https://doi.org/10.1124/jpet.109.159863.CrossRefPubMedPubMedCentral

41.

Inoue K, Sodhi K, Puri N, Gotlinger KH, Cao J, Rezzani R, Falck JR, Abraham NG, Laniado-Schwartzman M. Endothelial-specific CYP4A2 overexpression leads to renal injury and hypertension via increased production of 20-HETE. Am J Physiol Renal Physiol. 2009;297(4):F875–84. https://doi.org/10.1152/ajprenal.00364.2009.CrossRefPubMedPubMedCentral

42.

Cheng J, Ou JS, Singh H, Falck JR, Narsimhaswamy D, Pritchard KA Jr, Schwartzman ML. 20-hydroxyeicosatetraenoic acid causes endothelial dysfunction via eNOS uncoupling. Am J Physiol Heart Circ Physiol. 2008;294(2):H1018–26. https://doi.org/10.1152/ajpheart.01172.2007.CrossRefPubMed

43.

Alonso-Galicia M, Maier KG, Greene AS, Cowley AW Jr, Roman RJ. Role of 20-hydroxyeicosatetraenoic acid in the renal and vasoconstrictor actions of angiotensin II. Am J Physiol Regul Integr Comp Physiol. 2002;283(1):R60–8. https://doi.org/10.1152/ajpregu.00664.2001.CrossRefPubMed

44.

Sodhi K, Wu CC, Cheng J, Gotlinger K, Inoue K, Goli M, Falck JR, Abraham NG, Schwartzman ML. CYP4A2-induced hypertension is 20-hydroxyeicosatetraenoic acid- and angiotensin II-dependent. Hypertension. 2010;56(5):871–8. https://doi.org/10.1161/HYPERTENSIONAHA.110.154559.CrossRefPubMed

45.

Garcia V, Shkolnik B, Milhau L, Falck JR, Schwartzman ML. 20-HETE activates the transcription of angiotensin-converting enzyme via Nuclear Factor-κB translocation and promoter binding. J Pharmacol Exp Ther. 2016;356(3):525–33. https://doi.org/10.1124/jpet.115.229377.CrossRefPubMedPubMedCentral

46.

Kim DH, Puri N, Sodhi K, Falck JR, Abraham NG, Shapiro J, Schwartzman ML. Cyclooxygenase-2 dependent metabolism of 20-HETE increases adiposity and adipocyte enlargement in mesenchymal stem cell-derived adipocytes. J Lipid Res. 2013;54(3):786–93. https://doi.org/10.1194/jlr.M033894.CrossRefPubMedPubMedCentral

47.

Peterson LR. To lose weight or not to lose weight, that is the big question–in obesity-related heart failure. Diabetes. 2015;64(5):1509–10. https://doi.org/10.2337/db15-0003.CrossRefPubMedPubMedCentral

48.

Imig JD. Epoxyeicosanoids in hypertension. Physiol Res. 2019;68(5):695–704. https://doi.org/10.33549/physiolres.934291.CrossRefPubMed

49.

Das UN. Arachidonic acid in health and disease with focus on hypertension and diabetes mellitus: a review. J Adv Res. 2018;11:43–55. https://doi.org/10.1016/j.jare.2018.01.002.CrossRefPubMedPubMedCentral

50.

Luther JM, Brown NJ. Epoxyeicosatrienoic acids and glucose homeostasis in mice and men. Prostaglandins Other Lipid Mediat. 2016;125:2–7. https://doi.org/10.1016/j.prostaglandins.2016.07.010.CrossRefPubMedPubMedCentral

51.

Drenjančević I, Jukić I, Mihaljević Z, Kibel A. The Metabolites of Arachidonic Acid in Microvascular Function. In (Ed. by H. Lenasi), Microcirculation Revisited - From Molecules to Clinical Practice. IntechOpen; 2016. https://doi.org/10.5772/64676

52.

Luo P, Chang HH, Zhou Y, Zhang S, Hwang SH, Morisseau C, Wang CY, Inscho EW, Hammock BD, Wang MH. Inhibition or deletion of soluble epoxide hydrolase prevents hyperglycemia, promotes insulin secretion, and reduces islet apoptosis. J Pharmacol Exp Ther. 2010;334(2):430–8. https://doi.org/10.1124/jpet.110.167544.CrossRefPubMedPubMedCentral

53.

Ramirez CE, Shuey MM, Milne GL, Gilbert K, Hui N, Yu C, Luther JM, Brown NJ. Arg287Gln variant of EPHX2 and epoxyeicosatrienoic acids are associated with insulin sensitivity in humans. Prostaglandins Other Lipid Mediat. 2014;113–115:38–44. https://doi.org/10.1016/j.prostaglandins.2014.08.001.CrossRefPubMed

54.

Randhawa PK, Jaggi AS. TRPV4 channels: physiological and pathological role in cardiovascular system. Basic Res Cardiol. 2015;110(6):54. https://doi.org/10.1007/s00395-015-0512-7.CrossRefPubMed

55.

Campbell WB, Gebremedhin D, Pratt PF, Harder DR. Identification of epoxyeicosatrienoic acids as endothelium-derived hyperpolarizing factors. Circ Res. 1996;78(3):415–23. https://doi.org/10.1161/01.res.78.3.415.CrossRefPubMed

56.

Fleming I. Cytochrome P450 2 C is an EDHF synthase in coronary arteries. Trends Cardiovasc Med. 2000;10(4):166–70. https://doi.org/10.1016/s1050-1738(00)00065-7.CrossRefPubMed

57.

Imig JD, Falck JR, Wei S, Capdevila JH. Epoxygenase metabolites contribute to nitric oxide-independent afferent arteriolar vasodilation in response to bradykinin. J Vasc Res. 2001;38(3):247–55. https://doi.org/10.1159/000051053.CrossRefPubMed

58.

Lai J, Chen C. The role of epoxyeicosatrienoic acids in Cardiac Remodeling. Front Physiol. 2021;12:642470. https://doi.org/10.3389/fphys.2021.642470.CrossRefPubMedPubMedCentral

59.

Bellien J, Joannides R, Iacob M, Arnaud P, Thuillez C. Evidence for a basal release of a cytochrome-related endothelium-derived hyperpolarizing factor in the radial artery in humans. Am J Physiol Heart Circ Physiol. 2006;290(4):H1347–52. https://doi.org/10.1152/ajpheart.01079.2005.CrossRefPubMed

60.

Imig JD, Zhao X, Capdevila JH, Morisseau C, Hammock BD. Soluble epoxide hydrolase inhibition lowers arterial blood pressure in angiotensin II hypertension. Hypertension. 2002;39(2 Pt 2):690–4. https://doi.org/10.1161/hy0202.103788.CrossRefPubMed

61.

Capdevila JH, Falck JR, Imig JD. Roles of the cytochrome P450 arachidonic acid monooxygenases in the control of systemic blood pressure and experimental hypertension. Kidney Int. 2007;72(6):683–9. https://doi.org/10.1038/sj.ki.5002394.CrossRefPubMed

62.

Zhao X, Pollock DM, Inscho EW, Zeldin DC, Imig JD. Decreased renal cytochrome P450 2 C enzymes and impaired vasodilation are associated with angiotensin salt-sensitive hypertension. Hypertension. 2003;41(3 Pt 2):709–14. https://doi.org/10.1161/01.HYP.0000047877.36743.FA.CrossRefPubMed

63.

Zhao X, Dey A, Romanko OP, Stepp DW, Wang MH, Zhou Y, Jin L, Pollock JS, Webb RC, Imig JD. Decreased epoxygenase and increased epoxide hydrolase expression in the mesenteric artery of obese Zucker rats. Am J Physiol Regul Integr Comp Physiol. 2005;288(1):R188–96. https://doi.org/10.1152/ajpregu.00018.2004.CrossRefPubMed

64.

Ai D, Pang W, Li N, Xu M, Jones PD, Yang J, Zhang Y, Chiamvimonvat N, Shyy JY, Hammock BD, Zhu Y. Soluble epoxide hydrolase plays an essential role in angiotensin II-induced cardiac hypertrophy. Proc Natl Acad Sci U S A. 2009;106(2):564–9. https://doi.org/10.1073/pnas.0811022106.CrossRefPubMedPubMedCentral

65.

Lee CR, Imig JD, Edin ML, Foley J, DeGraff LM, Bradbury JA, Graves JP, Lih FB, Clark J, Myers P, Perrow AL, Lepp AN, Kannon MA, Ronnekleiv OK, Alkayed NJ, Falck JR, Tomer KB, Zeldin DC. Endothelial expression of human cytochrome P450 epoxygenases lowers blood pressure and attenuates hypertension-induced renal injury in mice. FASEB J. 2010;24(10):3770–81. https://doi.org/10.1096/fj.10-160119.CrossRefPubMedPubMedCentral

66.

Imig JD, Elmarakby A, Nithipatikom K, Wei S, Capdevila JH, Tuniki VR, Sangras B, Anjaiah S, Manthati VL, Sudarshan Reddy D, Falck JR. Development of epoxyeicosatrienoic acid analogs with in vivo anti-hypertensive actions. Front Physiol. 2010;1:157. https://doi.org/10.3389/fphys.2010.00157.CrossRefPubMedPubMedCentral

67.

Hye Khan MA, Pavlov TS, Christain SV, Neckář J, Staruschenko A, Gauthier KM, Capdevila JH, Falck JR, Campbell WB, Imig JD. Epoxyeicosatrienoic acid analogue lowers blood pressure through vasodilation and sodium channel inhibition. Clin Sci (Lond). 2014;127(7):463–74. https://doi.org/10.1042/CS20130479.CrossRefPubMed

68.

Xiao B, Li X, Yan J, Yu X, Yang G, Xiao X, Voltz JW, Zeldin DC, Wang DW. Overexpression of cytochrome P450 epoxygenases prevents development of hypertension in spontaneously hypertensive rats by enhancing atrial natriuretic peptide. J Pharmacol Exp Ther. 2010;334(3):784–94. https://doi.org/10.1124/jpet.110.167510.CrossRefPubMedPubMedCentral

69.

Campbell WB, Imig JD, Schmitz JM, Falck JR. Orally active epoxyeicosatrienoic acid analogs. J Cardiovasc Pharmacol. 2017;70(4):211–24. https://doi.org/10.1097/FJC.0000000000000523.CrossRefPubMedPubMedCentral

70.

Imig JD, Hammock BD. Soluble epoxide hydrolase as a therapeutic target for cardiovascular diseases. Nat Rev Drug Discov. 2009;8(10):794–805. https://doi.org/10.1038/nrd2875.CrossRefPubMedPubMedCentral

71.

Yang L, Cheriyan J, Gutterman DD, Mayer RJ, Ament Z, Griffin JL, Lazaar AL, Newby DE, Tal-Singer R, Wilkinson IB. Mechanisms of vascular dysfunction in COPD and Effects of a Novel Soluble Epoxide hydrolase inhibitor in smokers. Chest. 2017;151(3):555–63. https://doi.org/10.1016/j.chest.2016.10.058.CrossRefPubMed

72.

Capdevila J, Wang W. Role of cytochrome P450 epoxygenase in regulating renal membrane transport and hypertension. Curr Opin Nephrol Hypertens. 2013;22(2):163–9. https://doi.org/10.1097/MNH.0b013e32835d911e.CrossRefPubMedPubMedCentral

73.

Zhao X, Yamamoto T, Newman JW, Kim IH, Watanabe T, Hammock BD, Stewart J, Pollock JS, Pollock DM, Imig JD. Soluble epoxide hydrolase inhibition protects the kidney from hypertension-induced damage. J Am Soc Nephrol. 2004;15(5):1244–53. https://jasn.asnjournals.org/content/15/5/1244.long. Accessed 29.08.2022.PubMed

74.

Imig JD. Prospective for cytochrome P450 epoxygenase cardiovascular and renal therapeutics. Pharmacol Ther. 2018;192:1–19. https://doi.org/10.1016/j.pharmthera.2018.06.015.CrossRefPubMedPubMedCentral

75.

Capdevila JH, Pidkovka N, Mei S, Gong Y, Falck JR, Imig JD, Harris RC, Wang W. The Cyp2c44 epoxygenase regulates epithelial sodium channel activity and the blood pressure responses to increased dietary salt. J Biol Chem. 2014;289(7):4377–86. https://doi.org/10.1074/jbc.M113.508416.CrossRefPubMed

76.

Tiwari S, Packer RK, Hu X, Sugimura Y, Verbalis JG, Ecelbarger CA. Increased renal alpha-ENaC and NCC abundance and elevated blood pressure are independent of hyperaldosteronism in vasopressin escape. Am J Physiol Renal Physiol. 2006;291(1):F49–F57. https://doi.org/10.1152/ajprenal.00390.2005.CrossRefPubMed

77.

Imig JD. Epoxyeicosatrienoic acids, hypertension, and kidney injury. Hypertension. 2015;65(3):476–82. https://doi.org/10.1161/HYPERTENSIONAHA.114.03585.CrossRefPubMed

78.

Sun P, Antoun J, Lin DH, Yue P, Gotlinger KH, Capdevila J, Wang WH. Cyp2c44 epoxygenase is essential for preventing the renal sodium absorption during increasing dietary potassium intake. Hypertension. 2012;59(2):339–47. https://doi.org/10.1161/HYPERTENSIONAHA.111.178475.CrossRefPubMed

79.

Sun P, Liu W, Lin DH, Yue P, Kemp R, Satlin LM, Wang WH. Epoxyeicosatrienoic acid activates BK channels in the cortical collecting duct. J Am Soc Nephrol. 2009;20(3):513–23. https://doi.org/10.1681/ASN.2008040427.CrossRefPubMedPubMedCentral

80.

Manhiani M, Quigley JE, Knight SF, Tasoobshirazi S, Moore T, Brands MW, Hammock BD, Imig JD. Soluble epoxide hydrolase gene deletion attenuates renal injury and inflammation with DOCA-salt hypertension. Am J Physiol Renal Physiol. 2009;297(3):F740–8. https://doi.org/10.1152/ajprenal.00098.2009.CrossRefPubMedPubMedCentral

81.

Node K, Huo Y, Ruan X, Yang B, Spiecker M, Ley K, Zeldin DC, Liao JK. Anti-inflammatory properties of cytochrome P450 epoxygenase-derived eicosanoids. Science. 1999;285(5431):1276–9. https://doi.org/10.1126/science.285.5431.1276.CrossRefPubMedPubMedCentral

82.

Deng Y, Edin ML, Theken KN, Schuck RN, Flake GP, Kannon MA, DeGraff LM, Lih FB, Foley J, Bradbury JA, Graves JP, Tomer KB, Falck JR, Zeldin DC, Lee CR. Endothelial CYP epoxygenase overexpression and soluble epoxide hydrolase disruption attenuate acute vascular inflammatory responses in mice. FASEB J. 2011;25(2):703–13. https://doi.org/10.1096/fj.10-171488.CrossRefPubMedPubMedCentral

83.

Olearczyk JJ, Quigley JE, Mitchell BC, Yamamoto T, Kim IH, Newman JW, Luria A, Hammock BD, Imig JD. Administration of a substituted adamantyl urea inhibitor of soluble epoxide hydrolase protects the kidney from damage in hypertensive Goto-Kakizaki rats. Clin Sci (Lond). 2009;116(1):61–70. https://doi.org/10.1042/CS20080039.CrossRefPubMed

84.

Imig JD. Epoxides and soluble epoxide hydrolase in cardiovascular physiology. Physiol Rev. 2012;92(1):101–30. https://doi.org/10.1152/physrev.00021.2011.CrossRefPubMed

85.

He Z, Zhang X, Chen C, Wen Z, Hoopes SL, Zeldin DC, Wang DW. Cardiomyocyte-specific expression of CYP2J2 prevents development of cardiac remodelling induced by angiotensin II. Cardiovasc Res. 2015;105(3):304–17. https://doi.org/10.1093/cvr/cvv018.CrossRefPubMedPubMedCentral

86.

Yang L, Ni L, Duan Q, Wang X, Chen C, Chen S, Chaugai S, Zeldin DC, Tang JR, Wang DW. CYP epoxygenase 2J2 prevents cardiac fibrosis by suppression of transmission of pro-inflammation from cardiomyocytes to macrophages. Prostaglandins Other Lipid Mediat. 2015;116–117:64–75. https://doi.org/10.1016/j.prostaglandins.2015.01.004.CrossRefPubMedPubMedCentral

87.

Dreisbach AW, Japa S, Sigel A, Parenti MB, Hess AE, Srinouanprachanh SL, Rettie AE, Kim H, Farin FM, Hamm LL, Lertora JJ. The prevalence of CYP2C8, 2C9, 2J2, and soluble epoxide hydrolase polymorphisms in African Americans with hypertension. Am J Hypertens. 2005;18(10):1276–81. https://doi.org/10.1016/j.amjhyper.2005.04.019.CrossRefPubMed

88.

King LM, Gainer JV, David GL, Dai D, Goldstein JA, Brown NJ, Zeldin DC. Single nucleotide polymorphisms in the CYP2J2 and CYP2C8 genes and the risk of hypertension. Pharmacogenet Genomics. 2005;15(1):7–13. https://doi.org/10.1097/01213011-200501000-00002.CrossRefPubMed

89.

Polonikov AV, Ivanov VP, Solodilova MA, Khoroshaya IV, Kozhuhov MA, Ivakin VE, Katargina LN, Kolesnikova OE. A common polymorphism G-50T in cytochrome P450 2J2 gene is associated with increased risk of essential hypertension in a russian population. Dis Markers. 2008;24(2):119–26. https://doi.org/10.1155/2008/626430.CrossRefPubMedPubMedCentral

90.

Yu BN, Luo CH, Wang D, Wang A, Li Z, Zhang W, Mo W, Zhou HH. CYP2C9 allele variants in chinese hypertension patients and healthy controls. Clin Chim Acta. 2004;348(1–2):57–61. https://doi.org/10.1016/j.cccn.2004.04.028.CrossRefPubMed

91.

Ercan B, Ayaz L, Ciçek D, Tamer L. Role of CYP2C9 and CYP2C19 polymorphisms in patients with atherosclerosis. Cell Biochem Funct. 2008;26(3):309–13. https://doi.org/10.1002/cbf.1437.CrossRefPubMed

92.

Yang YN, Wang XL, Ma YT, Xie X, Fu ZY, Li XM, Chen BD, Liu F. Association of interaction between smoking and CYP 2C19*3 polymorphism with coronary artery disease in a Uighur population. Clin Appl Thromb Hemost. 2010;16(5):579–83. https://doi.org/10.1177/1076029610364522.CrossRefPubMed

93.

Ma Y, Ni W, Zhu W, Xiong Y, Deng X. Association of genetic polymorphisms of CYP 2C19 with hypertension in a chinese Han population. Blood Press. 2011;20(3):166–70. https://doi.org/10.3109/08037051.2010.542640.CrossRefPubMed

94.

Liu C, Kraja AT, Smith JA, Brody JA, Franceschini N, Bis JC, Rice K, Morrison AC, Lu Y, Weiss S, Guo X, Palmas W, Martin LW, Chen YD, Surendran P, Drenos F, Cook JP, Auer PL, Chu AY, Giri A, Zhao W, Jakobsdottir J, Lin LA, Stafford JM, Amin N, Mei H, Yao J, Voorman A, CHD Exome + Consortium; ExomeBP Consortium; GoT2DGenes Consortium; T2D-GENES Consortium, Larson MG, Grove ML, Smith AV, Hwang SJ, Chen H, Huan T, Kosova G, Stitziel NO, Kathiresan S, Samani N, Schunkert H, Deloukas P; Myocardial Infarction Genetics and CARDIoGRAM Exome Consortia, Li M, Fuchsberger C, Pattaro C, Gorski M, CKDGen Consortium, Kooperberg C, Papanicolaou GJ, Rossouw JE, Faul JD, Kardia SL, Bouchard C, Raffel LJ, Uitterlinden AG, Franco OH, Vasan RS, O’Donnell CJ, Taylor KD, Liu K, Bottinger EP, Gottesman O, Daw EW, Giulianini F, Ganesh S, Salfati E, Harris TB, Launer LJ, Dörr M, Felix SB, Rettig R, Völzke H, Kim E, Lee WJ, Lee IT, Sheu WH, Tsosie KS, Edwards DR, Liu Y, Correa A, Weir DR, Völker U, Ridker PM, Boerwinkle E, Gudnason V, Reiner AP, van Duijn CM, Borecki IB, Edwards TL, Chakravarti A, Rotter JI, Psaty BM, Loos RJ, Fornage M, Ehret GB, Newton-Cheh C, Levy D, Chasman DI. Meta-analysis identifies common and rare variants influencing blood pressure and overlapping with metabolic trait loci. Nat Genet. 2016;48(10):1162–1170. https://doi.org/10.1038/ng.3660

Titel: Association of CYP2C19 Polymorphic Markers with Cardiovascular Disease Risk Factors in Gas Industry Workers Undergoing Periodic Medical Examinations
verfasst von: Dmitry Alekseevich Sychev, MD, DSci, Professor, Academician of the Russian Academy of Sciences, rector, head of Clinical Pharmacology and Therapy department
Olga Alexandrovna Polyakova, MD, PhD, Assistant of the Department of Therapy and Polymorbid Pathology named after academician M.S. Vovsi
Zhannet Alimovna Sozaeva, MD, researcher in the Department of Molecular Medicine
Karin Badavievich Mirzaev, MD, DSci, vice-rector for research and innovation, director of the Research Institute of Molecular and Personalized Medicine
Olga Dmitrievna Ostroumova, MD, DSci, Professor, head of the Department of Therapy and Polymorbid Pathology named after Academician M.S. Vovsi
Publikationsdatum: 25.02.2023
Verlag: Springer International Publishing
Erschienen in: High Blood Pressure & Cardiovascular Prevention / Ausgabe 2/2023
Print ISSN: 1120-9879
Elektronische ISSN: 1179-1985
DOI: https://doi.org/10.1007/s40292-023-00567-4

Neu im Fachgebiet Kardiologie

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

29.05.2024 Herzinfarkt Nachrichten

Bei Menschen mit Typ-2-Diabetes sind die Chancen, einen Myokardinfarkt zu überleben, in den letzten 15 Jahren deutlich gestiegen – nicht jedoch bei Betroffenen mit Typ 1.

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

28.05.2024 Nebenwirkungen der Krebstherapie Nachrichten

Kardiotoxische Nebenwirkungen einer Therapie mit Immuncheckpointhemmern mögen selten sein – wenn sie aber auftreten, wird es für Patienten oft lebensgefährlich. Voruntersuchung und Monitoring sind daher obligat.

GLP-1-Agonisten können Fortschreiten diabetischer Retinopathie begünstigen

24.05.2024 Diabetische Retinopathie Nachrichten

Möglicherweise hängt es von der Art der Diabetesmedikamente ab, wie hoch das Risiko der Betroffenen ist, dass sich sehkraftgefährdende Komplikationen verschlimmern.

TAVI versus Klappenchirurgie: Neue Vergleichsstudie sorgt für Erstaunen

21.05.2024 TAVI Nachrichten

Bei schwerer Aortenstenose und obstruktiver KHK empfehlen die Leitlinien derzeit eine chirurgische Kombi-Behandlung aus Klappenersatz plus Bypass-OP. Diese Empfehlung wird allerdings jetzt durch eine aktuelle Studie infrage gestellt – mit überraschender Deutlichkeit.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Association of CYP2C19 Polymorphic Markers with Cardiovascular Disease Risk Factors in Gas Industry Workers Undergoing Periodic Medical Examinations

Abstract

Introduction

Aim

Materials and Methods

Results

Conclusion

Neu im Fachgebiet Kardiologie

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

GLP-1-Agonisten können Fortschreiten diabetischer Retinopathie begünstigen

TAVI versus Klappenchirurgie: Neue Vergleichsstudie sorgt für Erstaunen

Update Kardiologie

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Introduction

Aim

Materials and Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2023

Single-Pill Combination with Three Antihypertensive Agents to Improve Blood Pressure Control in Hypertension: Focus on Olmesartan-Based Combinations

An Expert Opinion on the Role of the Rosuvastatin/Amlodipine Single Pill Fixed Dose Combination in Cardiovascular Prevention

Hemodynamics and Arterial Stiffness in Response to Oral Glucose Loading in Individuals with Type II Diabetes and Controlled Hypertension

Risk Factors Control After an Acute Coronary Syndrome and Association with Major Adverse Cardiovascular Events: A Single Center Experience in Latin-America

An Updated Review on Glycoprotein IIb/IIIa Inhibitors as Antiplatelet Agents: Basic and Clinical Perspectives

Intergenerational Hypertension Prevention Education for Children and Family Members: A Longitudinal Assessment

Neu im Fachgebiet Kardiologie

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

GLP-1-Agonisten können Fortschreiten diabetischer Retinopathie begünstigen

TAVI versus Klappenchirurgie: Neue Vergleichsstudie sorgt für Erstaunen

Update Kardiologie